Arrowhead Pharmaceuticals is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15.77 – a decrease of 9.11% over the previous week. Arrowhead Pharmaceuticals employs 609 staff and has a trailing 12-month revenue of around $2.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $15.77 |
|---|---|
| 52-week range | $16.57 - $33.02 |
| 50-day moving average | $19.43 |
| 200-day moving average | $22.20 |
| Wall St. target price | $45.79 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-5.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.21 from 2025-03-10
| 1 week (2025-03-04) | -11.10% |
|---|---|
| 1 month (2025-02-13) | -20.41% |
| 3 months (2024-12-13) | -30.39% |
| 6 months (2024-09-13) | -29.22% |
| 1 year (2024-03-11) | -48.27% |
|---|---|
| 2 years (2023-03-10) | -42.19% |
| 3 years (2022-03-11) | 41.78 |
| 5 years (2020-03-11) | 28.56 |
| Revenue TTM | $2.5 million |
|---|---|
| Gross profit TTM | $2.5 million |
| Return on assets TTM | -47.71% |
| Return on equity TTM | -565.33% |
| Profit margin | 0% |
| Book value | $0.42 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.
Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.
Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $16.57 up to $33.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 0.922. This would suggest that Arrowhead Pharmaceuticals's shares are less volatile than average (for this exchange).
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc.
1. Choose a brokerage and download the app 2. Open an account 3. Research stocks 4. Fund the account 5. Purchase stocks 6. Monitor 7. Review
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Here are the best dividend stocks so far of the year based on dividend yield and analyst ratings.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.